Abstract 810P
Background
Recent studies suggested that tumor size reduction by means of pc prior to radical surgery might improve survival outcomes (SO) in CC pts. Whether pc has a beneficial effect in CC pts undergoing radical surgery in the form of total mesometrial resection (TMMR) is unclear. Because of the prevention of intraoperative tumor spillage by performing a closed colpotomy is essential to all TMMR, we hypothesized that pc would not affect SO in TMMR pts.
Methods
We performed a retrospective analysis of data which was collected in the Leipzig Mesometrial Resection trial. All pts had been treated for primary CC staged IB1 – IVA (2018-FIGO) by open abdominal hysterectomy performed as total or extended mesometrial resection (TMMR/EMMR). Recurrence-free (RFS) and overall survival (OAS) were analyzed. Cox proportional hazards regression models (Cox-R) were built to define the effect of pc. RFS and OAS within the conization group were analyzed to determine whether there is a difference between R0 (tumor removed completely) and R1 (tumor removed incompletely) conization.
Results
542 pts were included, of which 202 had received pc. After 1:1 propensity score matching including 163 pts with conization and 163 controls, pc was associated with significantly increased RFS (95.6% vs. 82.3%, HR 3.2, p<0.001) and OAS (99.2% vs. 85.6%, HR 6.4, p<0.001). In multivariable Cox-R pc was the only independent factor affecting RFS (HR 0.3, p<0.01). Analysis of the martingale residuals in a Cox regression null-model only including tumor-size revealed a continuous increase of recurrence risk with each increment in maximum tumor diameter for pts without pc, reaching a recurrence risk of 45% at a tumor size of 70 mm. In contrast, the recurrence risk for pts who had undergone pc plateaued at 12% at a tumor size of 37 mm. The sub analysis between R0 and R1 conization pts showed no difference in RFS and OAS.
Conclusions
In this study, pc was independently associated with improved survival in CC pts treated with TMMR/EMMR. Since intraoperative tumor spillage was avoided by closed colpotomy, factors other than the prevention of local tumor cell dissemination might play a role in improving survival. There is a need of further research to understand the concrete effect of pc to tumor biology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UKL-Universitätsklinikum Leipzig.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11